scholarly journals Efficiency and safety of direct-acting antiviral in cirrhotic hepatitis C infection patients: Real-life data from Turkey

2019 ◽  
Vol 30 (Supp1) ◽  
pp. 106-107
Author(s):  
Yesim Tasova ◽  
◽  
Tansu Yamazhan ◽  
Saban Esen ◽  
Nefise Cuvalci Oztoprak ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Real Life ◽  
Hepatitis C Infection ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting

scholarly journals Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C: Real-life Data

2021 ◽  
Vol 27 (2) ◽  
pp. 42-48
Author(s):  
Ayhan Balkan ◽  
Yasemin Balkan ◽  
Abdullah Emre Yıldırım ◽  
Buğra Tolga Konduk ◽  
Sezgin Barutçu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Real Life ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

Cells ◽  
2019 ◽  
Vol 8 (5) ◽  
pp. 416
Author(s):  
Nadia Marascio ◽  
Maria Mazzitelli ◽  
Grazia Pavia ◽  
Aida Giancotti ◽  
Giorgio Settimo Barreca ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Pediatric Patients ◽  
Real Life ◽  
Fixed Dose ◽  
Genotype 4 ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Dose Combination ◽  
Direct Acting

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.

HCV resistance-associated substitutions following direct-acting antiviral therapy failure – Real-life data from Poland

2021 ◽  
pp. 104949
Author(s):  
Miłosz Parczewski ◽  
Ewa Janczewska ◽  
Arkadiusz Pisula ◽  
Dorota Dybowska ◽  
Władysław Łojewski ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Real Life ◽  
Therapy Failure ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document